Takeda's gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks

It’s all about the proteins for Takeda’s latest deal with molecular engineering company Evozyne, which will see the two companies work together to develop new ones that can be incorporated into the next generation of gene therapy for rare diseases.

The deal is worth $400 million down the line, with an undisclosed “double-digit million” upfront payment and research funding payments, the companies said in a press release Tuesday morning.